Keating Financial Advisory Services’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Keating Financial Advisory Services's VRTX Position: Q2 2026 in Review
Keating Financial Advisory Services increased its Vertex Pharmaceuticals (VRTX) stake by 34% in Q2 2026, buying an estimated $63.4K and bringing the position to 559 shares worth $278K. The position accounts for 0.04% of the portfolio, ranked #303.
Keating Financial Advisory Services first reported a position in VRTX in Q4 2025 and has held it in 3 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Keating Financial Advisory Services held 559 shares of Vertex Pharmaceuticals worth $278K as of Q2 2026.
- Keating Financial Advisory Services bought 143 Vertex Pharmaceuticals shares in Q2 2026, an estimated $63.4K.
- Vertex Pharmaceuticals made up 0.04% of Keating Financial Advisory Services's portfolio in Q2 2026, its #303 holding.
- Keating Financial Advisory Services first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
- 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.